 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 1993 | Volume 119 Issue 4 | Pages 257-262
Objectives: To determine the efficacy of misoprostol for the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced duodenal and gastric ulcers in arthritis patients receiving NSAID therapy.
Design: A randomized, double-blind, multicenter, placebo-controlled trial.
Setting: Six hundred thirty-eight private, Veterans Affairs, health maintenance, and academic practices.
Patients: Six hundred thirty-eight patients with chronic inflammatory or noninflammatory arthritis who were taking an NSAID but who did not have a gastric or duodenal ulcer on screening endoscopy received treatment with ibuprofen, piroxicam, naproxen, sulindac, tolmetin, indomethacin, or diclofenac daily for 3 months. Four hundred fifty-five (71%) patients completed the trial.
Interventions: Patients meeting the entry criteria were randomized to receive either misoprostol, 200 µg, or placebo, four times a day for 12 weeks.
Main Outcome Measures: The endoscopy was repeated at 4, 8, and 12 weeks. The development of a duodenal or gastric ulcer (defined as a circumscribed mucosal defect
Results: By 12 weeks, a duodenal ulcer developed in 2 of 320 (0.6%; 95% CI, 0.2% to 3.9%) patients randomized to receive misoprostol, compared with 15 of 323 (4.6%; CI, 2.8% to 8%) patients receiving placebo (P = 0.002). A gastric ulcer developed in 6 of 320 (1.9%; [CI, 0.8% to 4.4%] patients, compared with in 25 of 323 (7.7%; CI, 5.1% to 11.4%), respectively.
Conclusion: Misoprostol significantly lowers the frequency of both duodenal and gastric ulcer development in patients who require long-term therapy with NSAIDS.
Author and Article Information
From the Veterans Affairs Medical Center/Baylor College of Medicine, Houston, Texas; University of California, Davis, Sacramento, California; University of Alabama at Birmingham, Birmingham, Alabama; Henry Ford Hospital, Detroit, Michigan; Rush Presbyterian, St. Luke's Medical Center, Chicago, Illinois; Wayne State University School of Medicine/Veterans Affairs Medical Center, Allen Park, Michigan; Veterans Affairs Medical Center, Martinez, California; G.D. Searle.
ARTICLE
Duodenal and Gastric Ulcer Prevention with Misoprostol in Arthritis Patients Taking NSAIDs
0.5 cm in diameter and with perceptible depth) was regarded as prophylactic failure.
Requests for Reprints: David Y. Graham, MD, Digestive Disease Section (111D), Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030.
Acknowledgments: The authors thank Tamara Schiller for her valuable assistance.
Grant Support: In part by a grant from G.D. Searle Company.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. B Jacobsen and B. B. Phillips Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs Ann. Pharmacother., September 1, 2004; 38(9): 1469 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey, L Laine, T Simon, H Quan, S Shingo, and J Evans Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study Gut, June 1, 2003; 52(6): 820 - 826. [Abstract] [Full Text]
|
|
|
|
|
|
A. P Guignard, S. Couray-Targe, C. Colin, and G. Chamba Economic Impact of Pharmacists' Interventions with Nonsteroidal Antiinflammatory Drugs Ann. Pharmacother., March 1, 2003; 37(3): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K.L. Chan, L. C.T. Hung, B. Y. Suen, J. C.Y. Wu, K. C. Lee, V. K.S. Leung, A. J. Hui, K. F. To, W. K. Leung, V. W.S. Wong, et al. Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis N. Engl. J. Med., December 26, 2002; 347(26): 2104 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. El-Serag, D. Y. Graham, P. Richardson, and J. M. Inadomi Prevention of Complicated Ulcer Disease Among Chronic Users of Nonsteroidal Anti-inflammatory Drugs: The Use of a Nomogram in Cost-effectiveness Analysis Arch Intern Med, October 14, 2002; 162(18): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Graham, N. M. Agrawal, D. R. Campbell, M. M. Haber, C. Collis, N. L. Lukasik, and B. Huang Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs: Results of a Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol vs Lansoprazole Arch Intern Med, January 28, 2002; 162(2): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R I Russell Non-steroidal anti-inflammatory drugs and gastrointestinal damage{---}problems and solutions Postgrad. Med. J., February 1, 2001; 77(904): 82 - 88. [Full Text]
|
|
|
|
 |
|
 C J Hawkey Outcomes studies of drug induced ulcer complications: do we need them and how should they be done? BMJ, July 29, 2000; 321(7256): 291 - 293. [Full Text]
|
|
|
|
 |
|
 S. J.O. V. van Zanten, N. Flook, N. Chiba, D. Armstrong, A. Barkun, M. Bradette, A. Thomson, F. Bursey, P. Blackshaw, D. Frail, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori Can. Med. Assoc. J., June 13, 2000; 162(90120): s3 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Simon, A. L. Weaver, D. Y. Graham, A. J. Kivitz, P. E. Lipsky, R. C. Hubbard, P. C. Isakson, K. M. Verburg, S. S. Yu, W. W. Zhao, et al. Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis: A Randomized Controlled Trial JAMA, November 24, 1999; 282(20): 1921 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Scharf, A. Mander, A. Ugoni, F. Vajda, and N. Christophidis A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology, July 1, 1999; 53(1): 197 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Wolfe, D. R. Lichtenstein, and G. Singh Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs N. Engl. J. Med., June 17, 1999; 340(24): 1888 - 1899. [Full Text] [PDF]
|
|
|
|
|
|
M. Koch, A. Dezi, F. Ferrario, and L. Capurso Prevention of Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Mucosal Injury: A Meta-analysis of Randomized Controlled Clinical Trials Arch Intern Med, November 11, 1996; 156(20): 2321 - 2332. [Abstract] [PDF]
|
|
|
|
|
|
G. Singh, D. R. Ramey, D. Morfeld, H. Shi, H. T. Hatoum, and J. F. Fries Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis: A Prospective Observational Cohort Study Arch Intern Med, July 22, 1996; 156(14): 1530 - 1536. [Abstract] [PDF]
|
|
|
|
|
|
A. S. Taha, N. Hudson, C. J. Hawkey, A. J. Swannell, P. N. Trye, J. Cottrell, S. G. Mann, T. J. Simon, R. D. Sturrock, and R. I. Russell Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory Drugs N. Engl. J. Med., May 30, 1996; 334(22): 1435 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Soll, Practice Parameters Committee of the American Coll, J. L. Achord, G. Bozymski, S. Brooks, F. Lanza, D. Lyon, G. Meyer, J. Reinus, M. Schuster, et al. Medical Treatment of Peptic Ulcer Disease: Practice Guidelines JAMA, February 28, 1996; 275(8): 622 - 629. [Abstract] [PDF]
|
|
|
|
|
|
N Maiden and R Madhok Misoprostol in patients taking non-steroidal anti-inflammatory drugs BMJ, December 9, 1995; 311(7019): 1518 - 1519. [Full Text]
|
|
|
|
|
|
J. G. Fort and H. D. Hoffman Cost-effectiveness and Misoprostol Arch Intern Med, July 10, 1995; 155(13): 1448 - 1448. [Abstract] [PDF]
|
|
|
|
 |
|
 Rational use of NSAIDs for musculoskeletal disorders DTB, December 1, 1994; 32(12): 91 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Laine and W. L. Peterson Bleeding Peptic Ulcer N. Engl. J. Med., September 15, 1994; 331(11): 717 - 727. [Full Text]
|
|
|
|
 |
|
 MISOPROSTOL AND NSAID-INDUCED DUODENAL ULCERS Journal Watch (General), September 3, 1993; 1993(903): 5 - 5. [Full Text]
|
|
